ORIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Oric Pharmaceuticals Inc (ORIC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as strong cash reserves and upcoming potential catalysts in its pipeline, the pre-market price drop, insider and hedge fund selling, and overbought technical indicators suggest caution. Additionally, the lack of significant recent congress trading data and no strong trading signals from Intellectia Proprietary Trading Signals further support a hold recommendation.
The stock's MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 84.641, suggesting the stock is overbought. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the pre-market price drop of -3.70% and the stock's proximity to resistance levels (R1: 13.564) suggest limited immediate upside potential.
Analysts have raised price targets recently, with targets ranging from $17 to $25, indicating confidence in the company's future prospects.
The company's ORIC-944 pipeline has potential as a best-in-class treatment for prostate cancer, with a clinical update expected in Q
Strong cash reserves of $412.3 million are expected to fund operations into the second half of 2028.
Hedge funds and insiders are selling the stock, with insider selling increasing by 773.65% over the last month.
The stock is overbought based on RSI, and the pre-market price drop of -3.70% raises concerns about immediate downside risk.
The company's financial performance shows widening net losses and declining EPS, which may deter long-term investors.
In Q4 2025, ORIC reported a narrower net loss of $30.51 million compared to $36.31 million in the previous year. However, full-year net loss widened to $129.47 million. The company exceeded EPS expectations in Q4 2025 (-$0.30 vs. -$0.36 expected) and has strong cash reserves of $412.3 million, including proceeds from a private placement and ATM program.
Analysts are bullish on ORIC, with multiple firms raising price targets recently (e.g., H.C. Wainwright to $25, Citi to $17, Piper Sandler to $22). Analysts highlight the company's pipeline potential and expect a catalyst-rich period over the next 12 months. However, the stock's current price is below all these targets, suggesting potential upside if catalysts materialize.
